A fixed combination of grazoprevir and elbasvir for the treatment of hepatitis c virus infection

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: YOO, Bong-Kyu (College of Pharmacy, Gachon University, Inchon, Korea, Republic Of)
  • Co-author(s): Bong-Kyu Yoo:
    Min-Gu Kang: College of Pharmacy, Gachon University, Incheon, Korea, Republic Of
    Min-Jung Kang: College of Pharmacy, Gachon University, Incheon, Korea, Republic Of
    Eun Kyung Choi: College of Pharmacy, Gachon University, Incheon, Korea, Republic Of
    Eunhee Ji: College of Pharmacy, Gachon University, Incheon, Korea, Republic Of
  • Abstract:

    Background

    There is a need to evaluate the efficacy and safety of the new drug, a fixed combination of grazoprevir and elbasvir (GE), in the treatment of hepatitis C virus (HCV) infection.

    Purpose

    The study aimed to systematically analyze pivotal Phase III clinical studies of GE with regard to the efficacy and safety of the new drug.

    Methods

    Data of..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login